title: Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
abstract: Eribulin mesylate (eribulin), an analogue of the marine natural product halichondrin B, is a microtubule-depolymerizing drug that has utility in the treatment of patients with breast cancer. Clinical trial results have demonstrated that eribulin treatment provides a survival advantage to patients with metastatic or locally advanced breast cancer previously treated with an anthracycline and a taxane. Furthermore, a pooled analysis of two pivotal phase III trials has demonstrated that eribulin also improves overall survival in several patient subgroups, including in women with HER2-negative disease and triple-negative breast cancer. This review covers the preclinical research that led to the clinical testing and approval of eribulin, as well as subsequent research that was prompted by distinct and unexpected effects of eribulin in the clinic. Initial studies with halichondrin B demonstrated unique effects on tubulin binding that resulted in distinct microtubule-dependent events and antitumor actions. Consistent with the actions of the natural product, eribulin has potent microtubule-depolymerizing activities and properties that distinguish it from other microtubule-targeting agents. Here, we review new results that further differentiate the effects of eribulin from other agents on peripheral nerves, angiogenesis, vascular remodeling, and epithelial-to-mesenchymal transition. Together, these data highlight the distinct properties of eribulin and begin to delineate the mechanisms behind the increased survival benefit provided by eribulin for patients.
authors.affiliation: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
authors.forename: Nicholas F
authors.initials: NF
authors.lastname: Dybdal-Hargreaves
authors.affiliation: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
authors.forename: April L
authors.initials: AL
authors.lastname: Risinger
authors.affiliation: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas Mooberry@uthscsa.edu.
authors.forename: Susan L
authors.initials: SL
authors.lastname: Mooberry
mesh_terms: D002986:Clinical Trials as Topic; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects; D004988:Ethers, Cyclic / Q000737:chemistry / Q000378:metabolism; D005260:Female; D005663:Furans / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000737:chemistry / Q000627:therapeutic use*; D018942:Macrolides / Q000737:chemistry / Q000378:metabolism; D008870:Microtubules / Q000187:drug effects* / Q000473:pathology; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000095662:Polyether Polyketides
chemical_list: D004988:Ethers, Cyclic; D005663:Furans; D007659:Ketones; D018942:Macrolides; C070519:halichondrin B; D000095662:Polyether Polyketides; C490954:eribulin
references.citation: Breast Cancer Res Treat. 2013 Jul;140(2):341-51
references.pmid: 23877339
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):51-63
references.pmid: 22215906
references.citation: Cancer Res. 2004 Aug 15;64(16):5760-6
references.pmid: 15313917
references.citation: J Cancer. 2014 Mar 20;5(5):320-7
references.pmid: 24723974
references.citation: Neurotox Res. 2013 Oct;24(3):338-44
references.pmid: 23637052
references.citation: Int J Dev Biol. 2011;55(3):261-8
references.pmid: 21710434
references.citation: Nat Rev Clin Oncol. 2011 Apr;8(4):244-50
references.pmid: 21283127
references.citation: Mol Cancer Ther. 2008 Jul;7(7):2003-11
references.pmid: 18645010
references.citation: Neurotherapeutics. 2009 Oct;6(4):620-9
references.pmid: 19789067
references.citation: Lancet. 2011 Mar 12;377(9769):914-23
references.pmid: 21376385
references.citation: Cancer Res. 2000 Sep 15;60(18):5045-51
references.pmid: 11016627
references.citation: Clin Transl Med. 2014 Jul 02;3:17
references.pmid: 25050175
references.citation: Cancer Res. 2011 Jan 15;71(2):496-505
references.pmid: 21127197
references.citation: Mol Cancer Ther. 2005 Jul;4(7):1086-95
references.pmid: 16020666
references.citation: Eur J Cancer. 1993;29A(9):1320-4
references.pmid: 8343277
references.citation: Cancer Res. 2011 Jun 1;71(11):3952-62
references.pmid: 21498637
references.citation: J Chem Inf Model. 2011 Jun 27;51(6):1393-404
references.pmid: 21539396
references.citation: Anticancer Res. 2012 May;32(5):1611-9
references.pmid: 22593439
references.citation: Nat Rev Cancer. 2005 Jun;5(6):423-35
references.pmid: 15928673
references.citation: Breast Cancer Res Treat. 2014 Dec;148(3):553-61
references.pmid: 25381136
references.citation: Br J Cancer. 2014 Mar 18;110(6):1497-505
references.pmid: 24569463
references.citation: Vasc Cell. 2014 Mar 01;6(1):3
references.pmid: 24581301
references.citation: Nat Prod Rep. 2013 Sep;30(9):1158-64
references.pmid: 23896896
references.citation: Am J Hematol. 2010 Aug;85(8):593-8
references.pmid: 20540157
references.citation: Expert Opin Pharmacother. 2010 Jun;11(9):1587-93
references.pmid: 20450446
references.citation: Clin Cancer Res. 2015 Mar 1;21(5):962-8
references.pmid: 25107915
references.citation: Eur J Cancer. 2006 Nov;42(16):2821-32
references.pmid: 16973349
references.citation: Neurotoxicology. 2013 Jul;37:231-9
references.pmid: 23711742
references.citation: Biochemistry. 2010 Feb 16;49(6):1331-7
references.pmid: 20030375
references.citation: Bioorg Med Chem Lett. 2000 May 15;10(10):1029-32
references.pmid: 10843209
references.citation: Cancer Sci. 2014 Oct;105(10):1334-42
references.pmid: 25060424
references.citation: J Biol Chem. 1990 Oct 5;265(28):17141-9
references.pmid: 2211617
references.citation: Bioorg Med Chem Lett. 2004 Nov 15;14(22):5551-4
references.pmid: 15482922
references.citation: Int J Exp Pathol. 2009 Jun;90(3):284-94
references.pmid: 19563611
references.citation: J Biol Chem. 1991 Aug 25;266(24):15882-9
references.pmid: 1874739
references.citation: Pediatr Blood Cancer. 2013 Aug;60(8):1325-32
references.pmid: 23553917
references.citation: Cancer Res. 2001 Feb 1;61(3):1013-21
references.pmid: 11221827
references.citation: Biochem Pharmacol. 1993 Jan 26;45(2):421-7
references.pmid: 8435093